N4 Pharma reports 2024 financial results

LONDON: N4 Pharma plc (AIM: N4P), a UK-based biotechnology company developing its proprietary Nuvec® gene delivery system for advanced cancer and disease therapies, announced its audited financial results for the year ended Dec. 31, 2024.

The company’s annual report and notice of its annual general meeting (AGM) have been distributed to shareholders. The AGM will take place at 11 a.m. on June 30, 2025, at Arch Law Limited Huckletree Bishopsgate in London. Documents are available on the company’s website at www.n4pharma.com.

Operational Highlights

• Focus on advancing RNA therapeutics using Nuvec® to secure commercial partnerships.
• Successful in vitro profiling of N4 101, an oral anti-inflammatory treatment for Inflammatory Bowel Disease (IBD), completed in December 2024.
• Positive in vivo results from University of Queensland studies in April 2024 demonstrated successful oral delivery of a Nuvec® capsule in mice.
• FDA application for orphan drug designation for ECP105, targeting post-glaucoma surgery scarring, filed in July 2024.
• Collaboration with SRI International in August 2024 confirmed Nuvec®’s ability to target specific cells.
• New patent filed for N4 101 in December 2024.

Post-Year-End Developments

• Dr. Alastair Smith appointed as independent non-executive director in January 2025, replacing David Templeton.
• £1.75 million ($2.2 million) raised through a placing and subscription in April 2025.
• Positive in vivo efficacy results for N4 101 in an IBD model showed reduced inflammation.
• Strengthened leadership team with industry experts in drug development and manufacturing.

Financial Summary

• Revenue rose to £7,282 ($9,200) from £1,953 ($2,470) in 2023.
• Operating loss narrowed to £1,221,101 ($1.54 million) from £1,424,594 ($1.8 million) in 2023.
• Year-end cash balance stood at £625,972 ($791,000), following a £630,000 ($796,000) fundraising in June 2024.

Nigel Theobald, CEO of N4 Pharma, said: “Nuvec® continues to generate compelling pre-clinical data, addressing the core challenge in RNA therapeutics — safe and effective delivery. With a strengthened team and funding, we are advancing commercial partnerships to unlock long-term value.”